+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID05519085

Comparing Mezigdomide, Bortezomib, and Dexamethasone Versus Pomalidomide, Bortezomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Led by Celgene · Updated on 2026-10-30

810

Participants Needed

266

Research Sites

359 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of two drug combinations for adults with relapsed or refractory multiple myeloma, a type of blood cancer. This study compares mezigdomide combined with bortezomib and dexamethasone MeziVd against pomalidomide combined with bortezomib and dexamethasone PVd in participants who have received one to three previous therapies including lenalidomide. The goal is to find out which treatment better controls the disease and how well patients tolerate these combinations. Participants are randomly assigned to receive either MeziVd or PVd treatment. Each drug is given at specified doses on certain days, and the study is open-label, meaning both participants and researchers know the assigned treatment. The study lasts up to approximately five years, allowing long-term monitoring and assessment of disease progression and survival. Additional measurements include drug levels in the blood, response rates, quality of life questionnaires, and safety evaluations. During the study, participants will have regular assessments to monitor their disease status, treatment response, and side effects. Progression-free survival, the time until disease worsens or death, is the main outcome measured. Other outcomes include overall survival, response quality, time to next treatment, and quality of life changes. Safety is closely monitored through adverse event reporting. The study provides important data to understand how these drug combinations work in relapsed or refractory multiple myeloma over an extended period.

CONDITIONS

Brief Title

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here